NasdaqGS - Delayed Quote • USD
Boundless Bio, Inc. (BOLD)
At close: June 7 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -0.8 | -0.8 | -6.76 | -4.59 |
| Low Estimate | -0.84 | -0.95 | -15.09 | -5.73 |
| High Estimate | -0.77 | -0.7 | -3.8 | -3.69 |
| Year Ago EPS | -- | -- | -- | -6.76 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2024 | |||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -0.55 |
| EPS Actual | -- | -- | -- | -12.27 |
| Difference | -- | -- | -- | -11.72 |
| Surprise % | -- | -- | -- | -2,130.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.8 | -0.8 | -6.76 | -4.59 |
| 7 Days Ago | -0.8 | -0.8 | -6.76 | -4.59 |
| 30 Days Ago | -0.65 | -0.72 | -2.77 | -3.55 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | BOLD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 9.10% |
| Next Qtr. | -- | -- | -- | 11.50% |
| Current Year | -- | -- | -- | 5.70% |
| Next Year | 32.10% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.34% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | Leerink Partners: Outperform | 4/22/2024 |
| Initiated | Guggenheim: Buy | 4/22/2024 |
| Initiated | Piper Sandler: Overweight | 4/22/2024 |
Related Tickers
CTNM Contineum Therapeutics, Inc.
16.31
+1.18%
LENZ LENZ Therapeutics, Inc.
15.58
+3.59%
INXB Inhibrx Biosciences, Inc.
15.86
+13.94%
MGX Metagenomi, Inc.
6.08
-8.30%
CNTA Centessa Pharmaceuticals plc
8.80
-1.35%
PEPG PepGen Inc.
16.57
-4.44%
ANRO Alto Neuroscience, Inc.
11.81
+0.34%
NBTX Nanobiotix S.A.
5.70
-8.06%
TYRA Tyra Biosciences, Inc.
19.78
-0.10%
LBPH Longboard Pharmaceuticals, Inc.
17.55
-1.07%